CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Congress Park Capital LLC

Congress Park Capital LLC cut its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 20.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 964,590 shares of the biotechnology company’s stock after selling 251,418 shares during the period. Congress Park Capital LLC’s holdings in CytomX Therapeutics were worth $994,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in CTMX. Virtu Financial LLC acquired a new position in CytomX Therapeutics during the 3rd quarter valued at about $104,000. Geode Capital Management LLC grew its stake in shares of CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after acquiring an additional 34,032 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of CytomX Therapeutics by 1.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 16,359 shares during the last quarter. FMR LLC increased its holdings in shares of CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after acquiring an additional 41,949 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company’s stock valued at $331,000 after purchasing an additional 26,373 shares during the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $5.77.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock opened at $0.85 on Friday. The business’s 50-day simple moving average is $1.04 and its two-hundred day simple moving average is $1.16. The company has a market cap of $66.29 million, a PE ratio of 4.98 and a beta of 1.03. CytomX Therapeutics, Inc. has a fifty-two week low of $0.79 and a fifty-two week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.23. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The firm had revenue of $33.43 million for the quarter, compared to analyst estimates of $18.92 million. During the same quarter in the prior year, the firm earned $0.04 earnings per share. As a group, analysts predict that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

CytomX Therapeutics Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.